Hemoglobin A1c, Blood
Use
Evaluating the long‑term control of blood glucose concentrations in patients with diabetes. Diagnosing diabetes. Identifying patients at increased risk for diabetes (prediabetes). This assay is not useful in determining day‑to‑day glucose control and should not be used to replace daily home testing of blood glucose.
Special Instructions
Not provided.
Limitations
The presence of hemoglobin variants (e.g., Hb Camperdown, Hb Fukuoka, Hb Philadelphia, Hb Wayne, Hb Raleigh) may interfere with measurements. In rare homozygous or double heterozygous variants (e.g., CC, SS, EE, SC), no HbA is present and no HbA1c value can be determined. In such cases, serum fructosamine may be helpful. Hemoglobinopathies and altered erythrocyte lifespan (e.g., hemolytic anemia, polycythemia, postsplenectomy) can lead to inaccurate results and misinterpretation; fructosamine is recommended in these scenarios.
FDA Approved
Methodology
Chromatography
Biomarkers
Hemoglobin A1c
Protein
LOINC Codes
- 4548-4 - HbA1c MFr Bld
- 4548-4 - HbA1c MFr Bld
Result Turnaround Time
0-1 day
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
2 mL
Container
Lavender top (EDTA) tube
Collection Instructions
Send specimen in original tube. Do not aliquot.
Causes for Rejection
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.